Boston Scientific Corporation
NYSE•BSX
CEO: Mr. Michael F. Mahoney
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 1992-05-19
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Contact Information
300 Boston Scientific Way, Marlborough, MA, 01752-1234, United States
508-683-4000
Market Cap
$102.58B
P/E (TTM)
35.5
34.4
Dividend Yield
--
52W High
$109.50
52W Low
$67.56
52W Range
Rank35Top 29.9%
4.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 4.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$5.29B+0.00%
4-Quarter Trend
EPS
$0.45+0.00%
4-Quarter Trend
FCF
$1.01B+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Strong 2025 Sales Growth Reported net sales reached $20.07B USD in 2025, showing 19.9% growth over 2024 results.
Net Income Jumps Significantly Reported net income attributable to stockholders was $2.90B USD, increasing 56.4% compared to the prior year.
Organic Growth Remains Robust Organic net sales growth reached 15.8% in 2025, primarily driven by strong commercial execution in Electrophysiology.
Adjusted EPS Rises Adjusted diluted EPS reached $3.06 USD, demonstrating 21.9% operational performance improvement versus 2024.
Risk Factors
Intense Market Competition Highly competitive medical device markets face pressure from large rivals, emerging low-cost offerings, and rapid technology changes.
Pricing and Market Size Declines Potential declines in market size, average selling prices, and procedure volumes could adversely affect financial results.
Geopolitical Supply Chain Risks Global conflicts and trade tensions create uncertainty impacting supply chains, increasing costs, and disrupting operations.
Regulatory Scrutiny Increases Increasing complexity of global regulations, including MDR and data privacy laws, raises compliance costs and risks.
Outlook
Strategic Growth Imperatives Strategic imperatives focus on strengthening category leadership and expanding presence into high-growth adjacencies across global markets.
Major Penumbra Acquisition Definitive agreement signed to acquire Penumbra for approximately $14.50B USD, expected to close during 2026.
R&D Investment Critical Continued investment in R&D supports development of next-generation technologies for future profitable sales growth.
Liquidity Position Strong Existing cash, operational cash flow, and credit facilities provide sufficient funding for operations and foreseeable future needs.
Peer Comparison
Revenue (TTM)
$397.96B
$75.60B
$62.58B
Gross Margin (Latest Quarter)
86.8%
81.9%
74.5%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| AMGN | $197.41B | 25.6 | 96.7% | 60.3% |
| ABT | $187.71B | 28.9 | 12.9% | 17.4% |
| GILD | $179.99B | 21.2 | 41.0% | 41.7% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
4.3%
Moderate Growth
4Q Net Income CAGR
-0.3%
Stable Profitability
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:Apr 21, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data